{
    "clinical_study": {
        "@rank": "164985", 
        "arm_group": {
            "arm_group_label": "BAY1129980", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate:\n\n        -  The side effects of BAY1129980 when given every 21 days different dose levels.\n\n        -  Determine the dose level of BAY1129980 that should be tested in future clinical\n           research studies.\n\n        -  Measure how much BAY1129980 is in the blood at specific times after administration.\n\n        -  If treatment with BAY1129980 shows any effect on reducing the tumor growth.\n\n        -  If there are specific biomarkers that might be able to explain why some patients\n           respond to treatment and others do not.\n\n        -  If treatment with BAY1129980 causes an immune response from the body against the drug\n           (immunogenicity)."
        }, 
        "brief_title": "Dose-escalation Study of BAY1129980", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The relatively restricted C4.4a expression pattern provides a target for the selective\n      delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable\n      antibody-drug conjugate. The subject population eligible for the current study will be those\n      subjects with advanced malignancies known to express C4.4a, which are refractory to standard\n      therapy or those without standard therapy or actively refusing any treatment, which would be\n      regarded as standard and in whom, in the opinion of the investigator, experimental therapy\n      with BAY1129980 may be beneficial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All subjects must be \u2265 18 years at the first screening examination / visit\n\n          -  All subjects must provide a tumor tissue sample  from [Formalin Fixed Paraffin\n             Embedded (FFPE) slides] archival tissue or fresh biopsy collected before Cycle 1, Day\n             1\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\n\n          -  Life expectancy of at least 12 weeks\n\n          -  Radiographically or clinically evaluable tumor. In the expansion phase, disease must\n             be measurable according to RECIST 1.1.\n\n          -  Adequate bone marrow, liver, and renal function\n\n          -  Histologically or cytologically confirmed solid tumors known to express C4.4a (eg,\n             carcinomas of the lung, head & neck SCC, esophagus SCC (squamous cell\n             carcinoma),colon, ovary, prostate, and breast) that are refractory to any standard\n             therapy, or have no standard therapy available, or for which subjects actively refuse\n             any treatment that would be regarded as standard and in whom, in the opinion of the\n             investigator, experimental therapy with BAY1129980 may be beneficial\n\n        Exclusion Criteria:\n\n          -  Anticancer chemotherapy, experimental cancer therapy, or cancer immunotherapy within\n             4 weeks prior to first dose study drug. Anticancer therapy is defined as any agent or\n             combination of agents with clinically proven anti tumor activity administered by any\n             route with the purpose of affecting the malignancy, either directly or indirectly,\n             including palliative and therapeutic endpoints.\n\n          -  Skin toxicity including but not limited to erythema, rash, ulceration, and open wound\n             that is still clinically present and considered as acute or chronic.\n\n          -  Subjects with psoriasis or other severe skin disease (eg, autoimmune skin disease,\n             active erythematous skin lesions, etc.)\n\n          -  Serious, non-healing wound, skin ulcer (of any grade), or bone fracture\n\n          -  Prior local radiotherapy is allowed if it is completed at least 4 weeks prior to the\n             first dose of study drug and the subject has evaluable lesions not previously\n             irradiated\n\n          -  Significant liver dysfunction determined as Child-Pugh score B or C\n\n          -  History of symptomatic metastatic brain or meningeal tumors unless the subject is >3\n             months from the end of definitive therapy before the first dose of study drug and has\n             clinically or radiologically no evidence of tumor growth.\n\n          -  History of clinically significant cardiac disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134197", 
            "org_study_id": "16044"
        }, 
        "intervention": {
            "arm_group_label": "BAY1129980", 
            "description": "Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.", 
            "intervention_name": "BAY1129980", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Oncology", 
            "Solid tumors", 
            "Antibody drug conjugate", 
            "Maximum tolerated dose"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "MTD is defined as the maximum dose at which the incidence of DLTs (dose limiting toxicities) during Cycle 1 is below 20%, or the maximum dose administered, whichever is achieved first during dose escalation", 
                "measure": "Maximum tolerated dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "C4.4a expression levels in tumour tissue", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Tumor response evaluation following RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Plasma concentration of BAY1129980 characterized by AUC (0-tlast)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Antidrug and antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 2 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}